+++ ๐ค๐ญ ๐ฟ๐ฒ๐๐๐น๐๐ ๐ฎ๐ฌ๐ฎ๐ฐ ๐ฎ๐ป๐ฑ ๐ฐ๐ผ๐ฟ๐ฝ๐ผ๐ฟ๐ฎ๐๐ฒ ๐๐ฝ๐ฑ๐ฎ๐๐ฒ +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: ๐ฌ ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTechโs goal of ten or more potentially registrational trials running by the end of 2024. ๐ฉน ๐๐ข๐ฉ๐๐-๐ญ๐ต: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. ๐ ๐๐ผ๐บ๐บ๐ฒ๐ฟ๐ฐ๐ถ๐ฎ๐น ๐ฟ๐ฒ๐ฎ๐ฑ๐ถ๐ป๐ฒ๐๐: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our firstย expected global #oncology product launch. ๐๐ถ๐ป๐ธ ๐๐ผ ๐ฃ๐ฅ ๐ฎ๐ป๐ฑ ๐ณ๐ผ๐ฟ๐๐ฎ๐ฟ๐ฑ-๐น๐ผ๐ผ๐ธ๐ถ๐ป๐ด ๐๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐๐: https://lnkd.in/ePDQiHbH ย
Keep growing!
Research and Development Formulation Scientist | Project Management enthusiast | Analytical Chemist | Material Scientist
3moDo you envision cash pile decrease on the balance sheet with the speed observed recently?